Abstract
Tigecycline is the first agent in the new class of glycylcycline antibiotics.
It’s expanded broad spectrum of activity, with demonstrated efficacy as monotherapy against clinically important Gram-positive and Gram-negative pathogens include also anerobes and antibiotic-resistant isolates.
It is presented the case of a 54 years old man, recently diagnosed with HIV infection, that had high fever and skin abscesses. The laboratory investigations showed a Systemic Inflammatory Response Syndrome.
After 10 days of treatment with Tygacil, 100 mg at first, then 50 mg/12 hours, surgical incision and drainage, antiinflammatory and symptomatic treatment, the patient’s symptoms disappeared and we started also the antiretroviral therapy.